Elkfork Partners’s Alnylam Pharmaceuticals ALNY Stock Holding History

Elkfork Partners’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$374K	Hold	4,648	–	–	0.01%	661
2019 Q2	$337K	Sell	4,648 -840	-15%	-$64.4K	0.01%	692
2019 Q1	$513K	Sell	5,488 -56	-1%	-$4.68K	0.01%	553
2018 Q4	$404K	Sell	5,544 -53,340	-91%	-$4.1M	0.01%	576
2018 Q3	$5.15M	Sell	58,884 -5,908	-9%	-$594K	0.12%	168
2018 Q2	$6.38M	Buy	64,792 +15,484	+31%	+$1.54M	0.16%	133
2018 Q1	$5.87M	Buy	+49,308	New	+$6.36M	0.16%	142

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Elkfork Partners's ALNY Position: Q3 2019 in Review

Elkfork Partners held its Alnylam Pharmaceuticals (ALNY) position steady in Q3 2019 at 4,648 shares worth $374K. The position accounts for 0.01% of the portfolio, ranked #661.

Elkfork Partners first reported a position in ALNY in Q1 2018 and has held it in 7 quarters since. The position peaked at $6.38M in Q2 2018. 281 funds tracked by Wall St. Rank hold ALNY as of Q3 2019.

Elkfork Partners held 4,648 shares of Alnylam Pharmaceuticals worth $374K as of Q3 2019.
Elkfork Partners left its Alnylam Pharmaceuticals share count unchanged in Q3 2019.
Alnylam Pharmaceuticals made up 0.01% of Elkfork Partners's portfolio in Q3 2019, its #661 holding.
Elkfork Partners first reported a position in Alnylam Pharmaceuticals in Q1 2018 and has held it in 7 quarters since.
Elkfork Partners's Alnylam Pharmaceuticals position peaked at $6.38M in Q2 2018.
281 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2019.

Based on Elkfork Partners's 13F filing for Q3 2019, filed 14 Nov 2019.